<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03961815</url>
  </required_header>
  <id_info>
    <org_study_id>3150-303-008</org_study_id>
    <nct_id>NCT03961815</nct_id>
  </id_info>
  <brief_title>Open-label Extension Study of Brazikumab in Crohn's Disease</brief_title>
  <official_title>An Open-label, Long-term Extension Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to permit participants who successfully completed or early
      terminated due to lack of efficacy from 3150-301-008, or successfully completed 3150-302-008,
      or discontinued from therapy due to termination of study 5170C00002 to receive open-label
      Brazikumab for an additional 52 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">February 3, 2020</start_date>
  <completion_date type="Anticipated">April 28, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 28, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the safety of long-term treatment with Brazikumab in patients with Crohn's disease (CD) based on the number of patients who experience one or more Treatment Emergent Adverse Events (TEAE)</measure>
    <time_frame>Across the 52-week treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with potentially clinically significant vital sign measurements</measure>
    <time_frame>Across the 52-week treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with potentially clinically significant laboratory values</measure>
    <time_frame>Across the 52-week treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with potentially clinically significant electrocardiograms</measure>
    <time_frame>Across the 52-week treatment period</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Brazikumab Induction Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous Brazikumab on Days 1, 29, and 57 followed by subcutaneous Brazikumab every 4 weeks through Week 52</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brazikumab Maintenance Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous Brazikumab every 4 weeks through Week 52 starting at Day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brazikumab</intervention_name>
    <description>Non-responders (or partial responders) to treatment from the lead-in studies may receive an induction dose regimen of intravenous Brazikumab on Days 1, 29, and 57 followed by subcutaneous Brazikumab every 4 weeks through Week 52</description>
    <arm_group_label>Brazikumab Induction Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brazikumab</intervention_name>
    <description>Lead-in study responders to treatment will receive subcutaneous Brazikumab every 4 weeks through Week 52 starting at Day 1</description>
    <arm_group_label>Brazikumab Maintenance Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Successful completion or early termination due to insufficient therapeutic response
             from 3150-301-008, successful completion of 301-302-008, or discontinued from
             treatment in D5170C00002 due to study termination

          -  No prior history of active TB and meets all TB-related criteria

          -  Consent to ileocolonoscopy at required time points.

          -  Agree to comply with contraception requirements for the study.

        Exclusion Criteria:

          -  Any participant with an unresolved AE from a lead-in study, that, in the
             investigator's opinion, would limit the participant's ability to participate in or
             complete the study.

          -  Current diagnosis of ischemic colitis, colonic mucosal dysplasia, primary
             sclerosingcholangitis, or any demyelinating condition.

          -  Any other condition or finding that, in the investigator's opinion, would either
             confound proper interpretation of the study or expose a participant to unacceptable
             risk.

          -  Participant meets criteria for discontinuation of study intervention during prior
             lead-in study.

          -  Participant requires additional immunosuppressive therapy (aside from permitted
             concomitant medication), biological treatment or prohibited treatment.

          -  Participant does not agree to refrain from receiving live vaccinations during the
             course of the study.

          -  Participant is planning to receive an investigational drug (other than study
             intervention) or investigational device at any time during Study 3150-303-008.

          -  Females who are pregnant, nursing, or planning a pregnancy during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aparna Sahoo, DO</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Trials Research</name>
      <address>
        <city>Lincoln</city>
        <state>California</state>
        <zip>95648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Consultants of Clearwater</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellness Clinical Research</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SIH Research</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanchez Clinical Research, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Professionals Clinical Research Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33165</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastro Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lovelace Scientific Resources, Inc.</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Lakes Medical Research, LLC</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centex Studies, Inc. - Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.AllerganClinicalTrials.com</url>
    <description>Additional information on study locations near you may be found at AllerganClinicalTrials.com. For any study not on AllerganClinicalTrials.com, please contact IR-CTRegistration@Allergan.com for assistance</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>May 8, 2019</study_first_submitted>
  <study_first_submitted_qc>May 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2019</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Allergan will share de-identified patient-level data and study-level data including protocols and clinical study reports for phase 2 - 4 trials completed after 2008 that are registered to ClinicalTrials.gov or EudraCT, have received regulatory approval in the United States and/or the European Union in a given indication and the primary manuscript from the trial has been published. To request access to the data, the researcher must sign a data use agreement and any shared data is to be used for non-commercial purposes. More information can be found on http://www.allerganclinicaltrials.com.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After having received regulatory approval in the United States and/or the European Union in a given indication and the primary manuscript from the trial has been published.</ipd_time_frame>
    <ipd_access_criteria>To request access to the data, the researcher must sign a data use agreement and any shared data is to be used for non-commercial purposes.</ipd_access_criteria>
    <ipd_url>http://www.allerganclinicaltrials.com/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

